[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Maanshan Shiqiye Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100639300","functionally-enhanced-limosilactobacillus-reuteri-probiotic-preparation-in-elderly-patients-with-functional-bowel-disorders-100639300",false,"NCT07624656","Functionally Enhanced Limosilactobacillus Reuteri Probiotic Preparation in Elderly Patients With Functional Bowel Disorders","An Exploratory Clinical Study on the Effects of a Functionally Enhanced Limosilactobacillus Reuteri Probiotic Preparation on Intestinal Immunity, Gut Microbiota Balance, and Intestinal Function in Elderly Patients With Functional Bowel Disorders","Inclusion Criteria:\n\n1.Diagnosis and Symptom Presentation: Participants must be diagnosed with functional gastrointestinal disorders (FGID) according to Rome IV criteria, including but not limited to:\n\n1. Functional constipation;\n2. Irritable bowel syndrome (IBS);\n3. Functional abdominal pain syndrome;\n4. Participants must have clear intestinal dysfunction-related symptoms such as abdominal pain, abdominal distension, difficulty in defecation, or changes in bowel habits, with organic gastrointestinal diseases excluded by clinical evaluation.\n\n2.Age and Disease Duration: Participants aged 50-65 years, with relevant symptoms persisting for at least 6 months, and having inadequate response to prior conventional treatment. Conventional treatments include but are not limited to: antidiarrheal agents (e.g., loperamide), gastrointestinal motility regulators (e.g., pinaverium bromide, trimebutine), intestinal microbiota products, or other commonly used drugs to improve diarrhea or regulate bowel function.\n\n3.Symptom Severity Assessment: Participants must have a total score of 10-20 on the functional bowel symptom scoring scale as specified in the study protocol (see Appendix).\n\n4.General Condition and Compliance: Participants must be able to understand the study purpose, provide written informed consent, and comply with the study procedures, including scheduled visits and collection of blood and fecal samples.\n\nExclusion Criteria:\n\n1. History or current presence of organic gastrointestinal diseases, such as gastrointestinal malignancy, inflammatory bowel disease (IBD), intestinal obstruction, or intestinal polyps.\n2. Presence of serious systemic diseases, including severe cardiovascular or cerebrovascular diseases (e.g., myocardial infarction within the past 6 months, New York Heart Association (NYHA) class III-IV heart failure, uncontrolled hypertension), significant liver or kidney dysfunction (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2× upper limit of normal, estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73m²), or uncontrolled diabetes (HbA1c ≥9%).\n3. Use of antibiotics, probiotics, or other drugs significantly affecting gut microbiota within 4 weeks prior to enrollment, or anticipated need to continue these drugs during the study.\n4. Pregnant or breastfeeding women, or those planning pregnancy during the study period.\n5. Participation in other clinical trials within 3 months prior to enrollment.\n6. Any other health conditions deemed unsuitable for participation by the investigator.","ALL","50 Years","65 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a single-center, open-label, single-arm interventional study designed to evaluate the effects of a functionally enhanced Limosilactobacillus reuteri probiotic preparation on intestinal immunity, gut microbiota balance, and intestinal function in elderly patients with functional bowel disorders. Participants aged 50-65 years with functional bowel disorders, including functional constipation, irritable bowel syndrome, or functional abdominal pain syndrome diagnosed according to Rome IV criteria, will receive the probiotic intervention.\n\nThe study will assess changes in senescence-associated secretory phenotype (SASP) expression levels to determine the extent of aging improvement, thereby evaluating the impact on intestinal immune aging. Clinical symptoms, including abdominal pain, abdominal distension, bowel movement frequency, and stool form, will also be recorded. In addition, changes in gut microbiota composition, key functional bacteria abundance, and tryptophan metabolites will be analyzed through fecal metagenomic and metabolomic approaches.\n\nSafety and tolerability will be monitored throughout the study by recording adverse events and assessing routine laboratory parameters, including blood count and serum biochemical markers. This study aims to explore the potential mechanisms by which the probiotic preparation may improve gut immune function and microbiota balance, providing evidence for future clinical applications in elderly patients with functional bowel disorders.",[27],"Functional Gastrointestinal Disorders",[29,30,27],"Functionally Enhanced Limosilactobacillus reuteri","Probiotic Intervention","NOT_YET_RECRUITING","2026-06-01",{"date":34,"type":35},"2026-06-03","ACTUAL",{"date":37,"type":21},"2026-06",{"date":39,"type":21},"2028-12",{"name":41,"class":42},"Maanshan Shiqiye Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100639576","probiotic-uricase-complex-preparation-for-improving-uric-acid-metabolism-in-patients-with-hyperuricemia-100639576","NCT07613164","Probiotic-Uricase Complex Preparation for Improving Uric Acid Metabolism in Patients With Hyperuricemia","An Exploratory Clinical Study to Evaluate the Effect of a Probiotic-Uricase Complex Preparation on Serum Uric Acid Reduction and Its Regulation of Gut Microbiota Composition and Uric Acid-Related Metabolic Profiles in Patients With Hyperuricemia","Inclusion Criteria:\n\n* Age 18-60 years.\n* Men with serum uric acid levels \\> 420 μmol\u002FL on 2 separate occasions (not on the same day), women with serum uric acid levels \\> 360 μmol\u002FL on 2 separate occasions (not on the same day).\n* Participants must sign an informed consent form and be able to cooperate with sample collection.\n\nExclusion Criteria:\n\n* A history of or current presence of a clearly defined organic intestinal disease, such as intestinal malignant tumor, inflammatory bowel disease, intestinal obstruction, or intestinal polyp.\n* Concurrent severe systemic diseases, including severe cardiovascular or cerebrovascular disease (eg., myocardial infarction within the past 6 months, NYHA Class III-IV heart failure, or uncontrolled hypertension), significant liver function abnormalities (ALT or AST \\> 2 times the upper limit of normal), moderate-to-severe renal insufficiency (eGFR \\\u003C 45 mL\u002Fmin\u002F1.73 m²) or uncontrolled diabetes (HbA1c ≥ 9%).\n* Use of antibiotic, probiotic preparation, or other drugs that may significantly alter the gut microbiota within 4 weeks prior to enrollment, or those requiring continued use of such drugs during the study.\n* Women who are pregnant or lactating, or who plan to become pregnant during the study.\n* Participants with severe tophus or gouty nephropathy.\n* Participants who have participated in another clinical trial within 3 months prior to enrollment.\n* Participants with other health problems that render them unsuitable for enrollment.","18 Years","60 Years",{"count":53,"type":21},45,[24],"This single-center, open-label, two-arm interventional study aims to evaluate the efficacy and safety of a probiotic-uricase complex preparation in patients with hyperuricemia. Participants aged 18 to 60 years with hyperuricemia will be assigned to either the intervention group or the control group. Participants in the intervention group will receive the probiotic-uricase complex preparation during a 2-week treatment period according to the study protocol in addition to conventional management, while participants in the control group will receive conventional management alone. Blood, urine, and fecal samples will be collected at baseline and during follow-up. The primary goal is to assess the change in serum uric acid from baseline after treatment. Secondary assessments include changes in uric acid-related metabolites in blood, urine, and feces, alterations in gut microbiota composition based on metagenomic analysis, and safety outcomes including laboratory parameters and adverse events. This study will explore whether the probiotic-uricase complex may serve as a safe and effective oral intervention for improving uric acid metabolism in patients with hyperuricemia.",[57],"Hyperuricemia, Gout",[30,59,60,61],"Hyperuricemia","Gout","Urease","2026-05-23",{"date":64,"type":35},"2026-05-29",{"date":66,"type":21},"2026-05",{"date":68,"type":21},"2029-05",{"name":41,"class":42},""]